Pulsenmore (NASDAQ:PLSM) reported a transformative fiscal year 2025, marked by a 374% increase in annual revenue and critical regulatory clearances that position the company for a high-growth trajectory in the remote-care sector.
The company's total revenue reached $12.5 million for the year, a sharp rise from 2024 levels.
A substantial portion of the top-line growth was attributed to a $9.6 million one-time settlement with GE, providing a significant non-dilutive capital injection.
This settlement, combined with disciplined operational spending, helped Pulsenmore narrow its annual net loss to $5 million, a 50% improvement over the $10 million loss reported in the previous year.
The company achieved several major infrastructure milestones during the period that management believes will drive long-term value.
Chief among these was the receipt of FDA clearance for its remote-use prenatal ultrasound system, allowing the company to officially begin commercial programs in the United States.
Furthermore, the company secured MDR/CE certification in Europe for its "Early-Screening" pregnancy product, expanding its total addressable market across the continent.
Pulsenmore ended the year with a liquid asset position of $21.7 million, which includes $7 million in cash as of December 31, 2025.
This balance sheet strength is expected to support the rollout of initial U.S. commercial partnerships throughout the first half of 2026.